Alimentary Pharmacology & Therapeutics · 2002 · 35 citations · 62 references
MedicineEndocrinologyOncologyEndocrine OncologyGastroenterologyGastrointestinal OncologyEndocrine Tumor DiagnosisEndocrine Tumor PrognosisGastric CancerGastric DiseasesGastric DisordersGastrointestinal PathologyBiomarkers Of Gastric CancerCarcinoid Tumor DiagnosisGastric Cancer ScreeningGastric MorphologyGastric Neuroendocrine NeoplasmsGastric Premalignant LesionsGastrointestinal Neuroendocrine TumorsPathology Of Gastric Cancer
BACKGROUND: Chronic hypergastrinaemia causes gastric enterochromaffin cell proliferation and carcinoid tumours. The only reliable means to diagnose enterochromaffin cell changes/carcinoids is by biopsy. AIM: To assess whether serum histamine, chromogranin A or serotonin and urinary N-methylimidazoleacetic acid or 5-hydroxyindoleacetic acid correlate with advanced enterochromaffin cell changes or gastric carcinoids in patients with gastrinomas. METHODS: Consecutive patients (n=145) had the above assays and endoscopy with gastric biopsies. RESULTS: Lower N-methylimidazoleacetic acid and chromogranin A levels (P < 0.0001) occurred in disease-free patients. In patients with active disease, the fasting serum gastrin levels correlated (P < 0.0001) with both chromogranin A and N-methylimidazoleacetic acid levels. Chromogranin A (P=0.005), but not N-methylimidazoleacetic acid, serotonin, 5-hydroxyindoleacetic acid or histamine levels, correlated with the enterochromaffin cell index. Carcinoids, but not advanced enterochromaffin cell changes only, were associated with higher chromogranin A and N-methylimidazoleacetic acid levels. CONCLUSIONS: Serum chromogranin A levels and urinary N-methylimidazoleacetic acid levels, but not serum histamine or serotonin or urinary 5-hydroxyindoleacetic acid, correlate with the presence of gastric carcinoids. However, no assay identified patients with advanced enterochromaffin cell changes only with high sensitivity/specificity. Thus, N-methylimidazoleacetic acid and chromogranin A levels are unable to identify patients with advanced changes in enterochromaffin cells and therefore neither can replace routine gastric biopsies.
62
Surgery to Cure the Zollinger–Ellison Syndrome
Jeffrey A. Norton, Douglas L. Fraker, H. Richard Alexander et al. · New England Journal of Medicine · 1999 · 505 citations · Full text
Fathia Gibril, James C. Reynolds, John L. Doppman et al. · Annals of Internal Medicine · 1996 · 444 citations
Medicine, Nuclear Medicine, Oncology +17
Gastric Carcinoids and Neuroendocrine Carcinomas: Pathogenesis, Pathology, and Behavior
Guido Rindi, Cesare Bordi, S. Rappel et al. · World Journal of Surgery · 1996 · 430 citations